How to Treat Subacute Thyroiditis: Medication Options and Management Strategies

Subacute thyroiditis, also known as de Quervain’s thyroiditis, is a self-limiting inflammatory disorder of the thyroid gland typically triggered by a viral infection. It presents with neck pain—often radiating to the jaw or ears—fever, fatigue, and transient thyrotoxicosis followed by a hypothyroid phase in some patients. Diagnosis relies on clinical evaluation, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), low radioactive iodine uptake on thyroid scintigraphy, and characteristic ultrasound findings such as heterogeneous echotexture with reduced vascularity.

Treatment is primarily symptomatic and tailored to disease severity. For mild cases—characterized by modest pain and low-grade fever—nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are first-line therapy and often sufficient to control inflammation and discomfort.

In moderate-to-severe cases—with intense pain, high fever, or significant systemic symptoms—oral glucocorticoids are the standard of care. Prednisone, initiated at 20–40 mg daily, typically produces rapid symptom relief within 24–72 hours. The dose is then gradually tapered over 4–6 weeks to minimize rebound inflammation and adrenal suppression. Prolonged or inappropriate tapering may increase relapse risk, so close clinical monitoring is essential.

Antithyroid medications (e.g., methimazole or propylthiouracil) are not indicated, as hormone excess results from destructive thyroiditis—not autonomous overproduction. Beta-blockers, such as propranolol, may be used short-term to manage adrenergic symptoms (e.g., palpitations, tremor, anxiety) during the thyrotoxic phase, but they do not alter the underlying disease course.

Thyroid hormone replacement (e.g., levothyroxine) is reserved for patients who develop persistent, symptomatic hypothyroidism—typically after the acute and subacute phases resolve. Most individuals recover full thyroid function spontaneously within 6–12 months; permanent hypothyroidism occurs in fewer than 5% of cases and warrants long-term hormone replacement.

Patients should avoid iodine supplementation and unnecessary thyroid imaging unless clinically indicated. Follow-up includes serial thyroid function tests (TSH, free T4, free T3) and clinical assessment to track recovery and identify rare complications, such as recurrent or atypical presentations requiring further evaluation.